Ascrinvacumab 产品活性：Ascrinvacumab (PF-03446962) 是一种人 IgG2 单克隆抗体，靶向 ALK-1。Ascrinvacumab 显示出与人 ALK1 的结合效能，Kd 值为 7 nM。Ascrinvacumab 可用于肝细胞癌 (HCC) 的研究。 产品来源： https://www.medchemexpress.cn/ascrinvacumab.html 研究领域：Protein Tyrosine Kinase/RTK 作用靶点：Anaplastic lymphoma kinase (ALK) In Vitro: Ascrinvacumab binds to cellular human ALK1 with a Kd value of 7 nm. Ascrinvacumab (30 min) blocks bone morphogenetic protein 9 (BMP9)- and fetal calf serum (FCS)-induced responses and mitigates BMP9-induced intensity and duration of Smad1 phosphorylation. Ascrinvacumab (0.01-10 μg/mL; 2 h) inhibits BMP9 binding to ALK1. Ascrinvacumab (40 μg/mL; 2 h) potently inhibits endothelial sprouting in human umbilical vein endothelial cells (HUVECs). In Vivo: Ascrinvacumab decreases human vessel density and improves antitumor efficacy when combined with bevacizumab (anti-VEGF) in mouse chimera tumor model. 相关产品：Crizotinib | Lorlatinib | Ceritinib | Entrectinib | Alectinib | Brigatinib | Repotrectinib | NVP-TAE 684 | GSK1838705A | MS4078 | AZD-3463 | CEP-37440 | Zotizalkib | Ensartinib dihydrochloride | R-268712 | Iruplinalkib | ALK inhibitor 2 | ALK-IN-1 | ASP3026 | KRCA-0008 | UNC5293 | TL13-112 | CPD-1224 | MS4077 | ALK kinase inhibitor-1 | Belizatinib | DDO-2728 品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；设有专业的实验中心和严格的质控、验证体系；提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；产品的生物活性多经各国客户实验验证；Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；与世界各大制药公司及知名科研机构建立了长期的合作。